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Background: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1) entry by
altering the CCR5 extracellular loops (ECL), such that the gp120 envelope glycoproteins (Env) no longer recognize
CCR5. The mechanisms of HIV-1 resistance to MVC, the only CCR5 antagonist licensed for clinical use are poorly
understood, with insights into MVC resistance almost exclusively limited to knowledge obtained from in vitro
studies or from studies of resistance to other CCR5 antagonists. To more precisely understand mechanisms of
resistance to MVC in vivo, we characterized Envs isolated from 2 subjects who experienced virologic failure on MVC.
Results: Envs were cloned from subjects 17 and 24 before commencement of MVC (17-Sens and 24-Sens) and after
virologic failure (17-Res and 24-Res). The Envs cloned during virologic failure showed broad divergence in resistance
levels, with 17-Res Env exhibiting a relatively high maximal percent inhibition (MPI) of ~90% in NP2-CD4/CCR5 cells
and peripheral blood mononuclear cells (PBMC), and 24-Res Env exhibiting a very low MPI of ~0 to 12% in both
cell types, indicating relatively “weak” and “strong” resistance, respectively. Resistance mutations were strain-specific
and mapped to the gp120 V3 loop. Affinity profiling by the 293-Affinofile assay and mathematical modeling using
VERSA (Viral Entry Receptor Sensitivity Analysis) metrics revealed that 17-Res and 24-Res Envs engaged MVC-bound
CCR5 inefficiently or very efficiently, respectively. Despite highly divergent phenotypes, and a lack of common
gp120 resistance mutations, both resistant Envs exhibited an almost superimposable pattern of dramatically
increased reliance on sulfated tyrosine residues in the CCR5 N-terminus, and on histidine residues in the CCR5 ECLs.
This altered mechanism of CCR5 engagement rendered both the resistant Envs susceptible to neutralization by a
sulfated peptide fragment of the CCR5 N-terminus.
Conclusions: Clinical resistance to MVC may involve divergent Env phenotypes and different genetic alterations in
gp120, but the molecular mechanism of resistance of the Envs studied here appears to be related. The increased
reliance on sulfated CCR5 N-terminus residues suggests a new avenue to block HIV-1 entry by CCR5 N-terminus
sulfopeptidomimetic drugs.
Keywords: HIV-1, Maraviroc, Resistance, Env, gp120, V3 loop, CCR5 N-terminus, CCR5 ECLs* Correspondence: gorry@burnet.edu.au
†Equal contributors
1Center for Virology, Burnet Institute, Melbourne, Victoria, Australia
4Department of Infectious Diseases, Monash University, Melbourne, Victoria,
Australia
Full list of author information is available at the end of the article
© 2013 Roche et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Roche et al. Retrovirology 2013, 10:43 Page 2 of 20
http://www.retrovirology.com/content/10/1/43Background
Human immunodeficiency virus type 1 (HIV-1) entry
into cells is mediated by the viral envelope glycoproteins
(Env) that decorate the surface of the virion (reviewed in
[1,2]). The Env complex is organized into trimers, and
consists of gp120, which is positioned on the surface of
the viral membrane and presents the receptor binding
surfaces of Env, and gp41, which is occluded by gp120
and anchors Env to the viral membrane. The primary
point of contact between Env and the host cell is be-
tween gp120 and cellular CD4. This leads to structural
rearrangements in gp120 that expose the binding site for
a cellular coreceptor, which is either of the chemokine
receptors CCR5 or CXCR4. Binding of gp120 to
coreceptor leads to further structural changes in Env
that expose the fusion peptide of gp41 that enables
virus-cell fusion and entry of the virion core into the
cell.
CCR5 comprises seven transmembrane helices that
form a central hydrophobic pocket. Extending from the
helices are the chemokine binding domains, comprising
the N-terminus and three extracellular loops (ECL1, 2
and 3). Current models of gp120 binding to CCR5
suggest that the crown of the gp120 V3 loop interacts
principally with the ECL2 region, while the gp120 bridg-
ing sheet that is formed between the C1, C2 and C4
domains of gp120 after CD4 binding, and the stem of
the V3 loop interact with the CCR5 N-terminus [3-6].
Sulfation of tyrosine residues in the CCR5 N-terminus,
particularly those at position 10 and 14, has been shown
to be important for HIV-1 entry [7,8].
CCR5 antagonists belong to a relatively new class of
HIV-1 antivirals known as entry inhibitors. They act by
binding to the hydrophobic pocket in CCR5 formed by
the transmembrane helices [9-14], which leads to struc-
tural alterations in the ECLs such that they are no longer
recognized by gp120 [10,13-15]. The structure of the N-
terminus does not appear to be affected by the binding
of CCR5 antagonists to CCR5 [15]. Thus, CCR5 antago-
nists do not competitively block the binding of Env to
CCR5, rather they are allosteric inhibitors of HIV-1
entry.
Maraviroc (MVC) [16,17] is the only CCR5 antagonist
that has been licensed for clinical use as an HIV-1 anti-
retroviral therapy [18]. Other CCR5 antagonist HIV-1
inhibitors that are no longer being pursued for clinical
development due to lack of clinical efficacy and/or ad-
verse side effects include vicriviroc (VVC) [19], aplaviroc
(APL) [20] and TAK-779 [21]. HIV-1 can develop clin-
ical resistance to CCR5 antagonists by two routes. The
first pathway is through emergence of minor CXCR4-
using HIV-1 variants that were not detected in plasma
prior to initiation of CCR5 antagonist therapy [22-29].
The second pathway to resistance is via continued use ofCCR5, which is characterized not by shifts in IC50 (as
would be expected for a competitive inhibitor), but
rather by reductions in the maximal percent inhibition
(MPI) [15,28,30-39]. Reductions in MPI are due to the
resistant virus developing the ability to bind to the
antagonist-modified form of CCR5 [34,35]. The plateau
height of the MPI is also informative, with viruses that
display a relatively high MPI (>80%) having relatively
inefficient usage of the antagonist-modified form of
CCR5 compared to unmodified CCR5, and viruses that
display a relatively low MPI (<20%) having relatively effi-
cient usage of the antagonist-modified form of CCR5
compared to unmodified CCR5.
Multiple studies have demonstrated that adaptive
changes in the gp120 V3 loop are almost always respon-
sible for the ability of resistant viruses to utilize the
antagonist-modified form of CCR5 [15,32-34,37,40-42],
although mutations in gp41 conferring this ability have
also been observed [43-45]. No signature pattern of
common amino acid mutations has been identified that
would predict resistance to CCR5 antagonists, such as
that which has been noted for HIV-1 resistance to the
fusion inhibitor enfuviritide. Rather, the V3 loop alter-
ations responsible for resistance to CCR5 antagonists ap-
pear to be strain specific [31,37,44,46,47].
The mechanisms underlying the ability of viruses with
resistance to CCR5 antagonists to recognize the
antagonist-modified form of CCR5 are incompletely
understood. Most studies suggest that resistant viruses
develop an increased reliance on the CCR5 N-terminus,
most likely signaling a shift in gp120 binding to a region
of CCR5 not modified by the binding of antagonist
[15,32,42,48-50]. However, a recent study of VVC resist-
ant strains showed heterogeneity in the ability of the
resistant viruses to interact with VVC-modified CCR5,
suggesting differing resistance mechanisms [38]. There is
also evidence to suggest that resistant viruses must still
interact with the drug modified ECLs, although the
degree to which this interaction is required may be
strain specific [15,51,52].
The vast majority of studies of HIV-1 resistance to
CCR5 antagonists, however, have been conducted on re-
sistant viruses that were generated in vitro [34,37,53,54],
or on viruses isolated from subjects failing therapy by
CCR5 antagonists that are no longer being pursued for
clinical development, such as VVC, APL and TAK-779
[30,32,33,42]. In contrast, there is a paucity of data on
MVC-resistant viruses arising in vivo [15,55]. Since dif-
ferent CCR5 antagonists cause subtly different structural
alterations in CCR5 [14,15], it is unlikely that mecha-
nisms of HIV-1 resistance to VVC, APL and TAK-779
can completely recapitulate those to MVC.
In this study we characterized the genetic, structural
and functional properties of MVC-resistant Envs derived
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in vivo, with comparison to Envs derived from the same
subjects prior to commencement of MVC. By measuring
the MPIs in different cell types and by conducting quan-
titative Env-CCR5 affinity profiling studies, we show that
the magnitude of MVC resistance was highly divergent
in these subjects, and was characterized by either a
highly efficient or a very inefficient ability of the resistant
Envs to engage MVC-bound CCR5. Despite highly diver-
gent resistance phenotypes and a lack of common gp120
resistance mutations, both resistant Envs exhibited an al-
most superimposable pattern of dramatically increased
reliance on sulfated tyrosine residues in the CCR5 N-
terminus, and on histidine residues in the CCR5 ECLs.
Furthermore, neither of the MVC-resistant Envs displayed
broad cross resistance to other CCR5 antagonists. To-
gether, our results suggest that clinical resistance to MVC
may involve divergent Env phenotypes and different
genetic alterations in gp120, but the molecular pathway to
resistance for the Envs studied here appears to be related.
Results and discussion
Characteristics of the MVC sensitive and MVC resistant
Env clones
Our previous studies revealed the molecular mecha-
nisms responsible for the recognition of the MVC-
modified form of CCR5 by a MVC-resistant Env that
was derived in vitro [51]. To determine how these mech-
anisms relate to those occurring in vivo, we obtained
HIV-1 Envs derived from two subjects (referred to as
subjects 17 and 24) who commenced MVC treatment
along with optimized background therapy as part of the
MOTIVATE phase III clinical trial, and who experienced
virologic failure associated with phenotypically-verified
MVC resistance [47,52,56,57]. Envs were isolated from
plasma before commencement of MVC treatment
(referred to as 17-Sens and 24-Sens Envs) and after viro-
logic failure (referred to as 17-Res and 24-Res Envs)
[57]. These Envs are representative of the dominant
circulating HIV-1 variants [52,56]. When subcloned into
the pSVIII-Env expression vector and used to produce
Env-pseudotyped luciferase reporter viruses, all 4 Envs
were shown to be specific for CCR5 in single round entry
assays with NP2-CD4/CCR5 and NP2-CD4/CXCR4 cells,Figure 1 V3 loop amino acid alterations responsible for resistance to
alterations shown in bold face were demonstrated to be associated with re
residues identical to the parental sensitive Envs, and dashes indicate gaps.with no evidence of specificity for CXCR4 detected (data
not shown). The Envs are also predicted to be of R5
phenotype by the Geno-2-Pheno coreceptor usage predic-
tion algorithm. Env sequence analysis showed amino acid
changes in the gp120 V3 loop that distinguished the resist-
ant Envs from the parental sensitive Envs (Figure 1). Of
note, 24-Res Env contains an insertion within the V3 loop
GPG crown, which is unusual for R5 Envs.
The MVC resistant Envs are highly divergent in their level
of resistance
To compare the magnitude of resistance between 17-Res
and 24-Res Envs, we first assessed their resistance pro-
files and measured their MPIs in NP2-CD4/CCR5 cells
and PBMC when pseudotyped onto luciferase reporter
viruses (Figure 2A). In both cell types 17-Sens and 24-
Sens Envs were completely inhibited by MVC, as dem-
onstrated by MPIs of ~100%, whilst 17-Res and 24-Res
Envs were incompletely inhibited by MVC. The extent
of incomplete inhibition of 17-Res and 24-Res Envs by
MVC was variable, with 17-Res Env displaying a rela-
tively high MPI in NP2-CD4/CCR5 cells (91.4 ± 1.3%)
and PBMC (87.4±2.4%), and 24-Res displaying a very
low MPI in NP2-CD4/CCR5 cells (12.5 ± 2.5%) (Table 1).
24-Res Env was completely insensitive to MVC inhib-
ition in PBMC, as shown by the lack of an obtainable
dose response curve (Figure 2A). These results suggest
that 17-Res Env has a relatively “weak” MVC resistance
phenotype, whereas 24-Res Env has a relatively “strong”
MVC resistance phenotype. The results further suggest
that resistance to MVC in HIV-1 infected subjects may
present in different ways and may potentially have differ-
ent clinical consequences. These MVC resistant Envs,
which display a wide divergence in resistance levels,
therefore offer a unique opportunity to better under-
stand alternative mechanisms of MVC resistance that
may arise in vivo.
MVC resistance by 17-Res and 24-Res Envs is not
associated with broad cross resistance to other CCR5
antagonists
Although MVC is the only CCR5 antagonist approved
for clinical use, other CCR5 antagonists are presently in
the developmental pipeline, so whether viruses that areMVC by viruses harbored by subjects 17 and 24. The V3 loop
sistance to MVC by 17-Res and 24-Res Envs [47,56]. Dots indicate
The numbering is based of the HXB2 Env amino acid sequence.
Figure 2 Profiles of resistance to MVC and cross-resistance to other CCR5 antagonists. Luciferase reporter viruses pseudotyped with Envs
from subject 17 or subject 24 were used to infect NP2-CD4/CCR5 (A, left panels) or PBMC (A, right panels) in the presence of increasing concentrations
of MVC. The same virus preparations were used to infect NP2-CD4/CCR5 cells in the presence of increasing concentrations of VVC or TAK-779 (B). Virus
inhibition curves were constructed as described in the Methods. The data points represent the mean and standard error of the mean from
quadruplicate wells, and are the results from 5 (MVC) or 3 (VVC and TAK-779) independent experiments. The independent PBMC experiments were
performed in cells obtained from different donors. Inhibition curves were constructed using Prism, version 4.0c (GraphPad).
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antagonists remains an important question. We there-
fore next determined the sensitivity of the panel of Envs
to inhibition by VVC and TAK-779 in NP2-CD4/CCR5
cells (Figure 2B) (Table 1). As expected, both 17-SensTable 1 MPIs of the HIV-1 Envs to MVC, VVC and TAK-779
Env MVC
MPI SEM 95% CI Resistance
phenotype
MPI SEM 95%
17-Sens 99.7 2.1 99.5-103.9 Sensitive 100.5 2.0 96.2-
17-Res 91.4 1.3 88.7-94.1 Weakly Resistant 98.3 1.9 94.4-
24-Sens 100.1 1.5 97.1-103.1 Sensitive 99.4 2.0 95.2-
24-Res 12.5 2.5 7.3-17.6 Strongly Resistant 91.4 2.2 86.9-
MPIs were determined in NP2-CD4/CCR5 cells, and are calculated from 3 (VVC, TAK-
MPI, maximal percent inhibition; SEM, standard error of the mean; CI, confidence inand 24-Sens Envs were completely inhibited by both
VVC and TAK-779, as demonstrated by MPIs of ~100%
by both CCR5 antagonists. 17-Res Env was also com-
pletely inhibited by VVC (MPI 98.3 ± 1.9%) and TAK-
779 (MPI 97.2 ± 5.4%), indicating that this “weakly”VVC TAK-779
CI Resistance
phenotype
MPI SEM 95% CI Resistance
phenotype
104.7 Sensitive 99.2 2.6 93.7-104.7 Sensitive
102.2 Sensitive 97.2 5.4 85.9-108.5 Sensitive
103.6 Sensitive 97.5 1.6 94.2-100.7 Sensitive
96.0 Weakly Cross-
resistant
94.7 2.3 89.9-99.5 Weakly Cross-
resistant
779) or 5 (MVC) independent experiments.
terval; MVC, maraviroc; VVC, vicriviroc.
Figure 3 V3 loop alterations contribute to MVC resistance in
subjects 17 and 24. Luciferase reporter viruses pseudotyped with
unmodified Envs from subject 17 or subject 24, or resistant Envs
carrying the V3 loop region of the respective sensitive Envs, were
used to infect NP2-CD4/CCR5 cells in the presence of increasing
concentrations of MVC (A). A similar experiment with unmodified
and mutant Envs from subject 17 was conducted in 293-Affinofile
cells that were induced to express maximal levels of CD4 and CCR5
as described previously [51,58] (B). Virus inhibition curves were
constructed as described in the Methods. The data points represent
the mean and standard error of the mean from quadruplicate wells,
and are the results from 4 independent experiments. Inhibition
curves were constructed using Prism, version 4.0c (GraphPad).
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other CCR5 antagonists. Although 24-Res Env was strongly
resistant to MVC with MPIs ~12% in NP2-CD4/CCR5 cells
(Figure 2A), it showed comparatively very modest levels of
cross resistance to VVC (91.4 ± 2.2%) and TAK-779 (94.7 ±
2.3%). These results show that despite divergent levels of
MVC resistance by 17-Res and 24-Res Envs, cross-
resistance to other CCR5 antagonists was either absent or
only weakly evident.
Broad cross resistance to multiple CCR5 antagonists
as a consequence of HIV-1 evolving resistance to one
particular CCR5 antagonist is relatively common for
viral strains that have developed resistance to VVC
[30,33,41,53], APL [39] and AD101 [40] which is a pre-
clinical precursor to VVC [13]. In contrast, strains that
have evolved resistance to MVC have shown either no
cross resistance to other CCR5 antagonists [34,51] or
narrow cross resistance [15], regardless of whether
resistance was generated in vitro or in vivo. These
results, in conjunction with our new data (Figure 2B),
suggest that a lack of appreciable cross resistance or a
narrow cross resistance profile may be unique to HIV-1
strains that have evolved resistance to MVC. It is known
that different CCR5 antagonists modify the structure of
CCR5 in subtly different ways [15]. Therefore, whilst ac-
quisition of the ability of HIV-1 to recognize the VVC-,
AD101-, or APL-modified forms of CCR5 can allow
recognition of other antagonist-modified forms of CCR5,
acquisition of the ability of HIV-1 to recognize the
MVC-modified form of CCR5 does not appear to lend
itself to cross resistance. Whilst these observations sug-
gest that HIV-1 that has developed resistance to MVC
may remain susceptible to new CCR5 antagonists should
they eventually reach the clinic, they underscore the
argument that the study of HIV-1 resistance to other
CCR5 antagonists most likely does not precisely predict
mechanisms of resistance to MVC.
Strain-specific V3 loop alterations contribute to MVC
resistance
To better understand whether the V3 loop alterations
associated with MVC resistance in subjects 17 and 24
contribute to the resistance phenotypes (Figure 1), we
next produced mutants of 17-Res and 24-Res that
contained the V3 loop alterations of 17-Sens and 24-
Sens Envs, respectively. We refer to these mutants as
17-Res(V3S) and 24-Res(V3S), respectively. The sensitiv-
ity of these Env mutants to MVC was first tested in
NP2-CD4/CCR5 cells, with comparison to the unmodi-
fied Envs (Figure 3A). 17-Res(V3S) was completely
inhibited by MVC in NP2-CD4/CCR5 cells, as demon-
strated by an MPI of 99.03 ± 1.85% (95% CI 95.25 – 102.8),
thus indistinguishable from the phenotype of 17-Sens Env
and significantly different to that of the parental 17-ResEnv (Table 1). 24-Res(V3S) was also completely inhibited
by MVC, as demonstrated by an MPI of 96.94 ± 1.51%
(95% CI 93.85 – 100.0). These results suggest that the V3
loop alterations shown in Figure 1 are necessary for MVC
resistance in subjects 17 and 24.
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was only subtly demonstrated in NP2-CD4/CCR5 cells,
we next repeated the MVC inhibition studies of 17-Sens,
17-Res and 17-Res(V3S) Envs in 293-Affinofile cells
induced to maximally express CD4 and CCR5, with the
rationale that MVC resistance phenotypes are usually
more pronounced in cell lines that express higher levels
of CCR5 [36,58] (Figure 3B). 17-Sens Env was completely
inhibited by MVC in the Affinofile cells, as demonstrated
by an MPI of 100.1 ± 5.10% (95% CI 89.70 – 110.5). In
contrast, 17-Res Env was incompletely inhibited, with an
MPI of 53.0 ± 9.56% (95% CI 33.53 – 72.47). The substan-
tially lower MPI to MVC by 17-Res Env in Affinofile cells
compared to NP2-CD4/CCR5 cells confirms that 17-Res
Env is genuinely MVC resistant. 17-Res(V3S) was com-
pletely inhibited by MVC in Affinofile cells as demonstrated
by an MPI of 105.5 ± 4.96 (95% CI 95.43 – 115.6), provid-
ing further evidence that the V3 loop alterations in 17-Res
Env are important for MVC resistance in this subject.
The magnitude of MVC resistance is determined by the
efficiency of the interaction with MVC-modified CCR5
The preceding studies suggest that 17-Res Env, which
has a comparatively high MPI to MVC, has a relatively
inefficient ability to recognize MVC-modified CCR5, but
that 24-Res Env, which has a comparatively low MPI to
MVC, has a very efficient ability to do so. We therefore
next used the 293-Affinofile affinity profiling system
[59,60] to quantify the ability of 17-Res and 24-Res Envs
to engage MVC-bound CCR5. In this system, CD4 and
CCR5 expression is controlled by separate inducible pro-
moters, permitting independent variation of CD4 and
CCR5 expression over a physiological concentration
range [59]. When 48 differentially-induced cell popula-
tions are subjected to single-round entry assays with
Env-pseudotyped luciferase reporter viruses and data
sets quantitatively analyzed by mathematical modeling
using the VERSA (Viral Entry Receptor Sensitivity Ana-
lysis) computational platform [59,60], vector metrics are
generated; vector angles measure the degree of CD4-
and CCR5-dependence, and vector magnitude measures
the efficiency of virus entry. These quantitative data can
be used to dissect gp120-CD4/CCR5 interactions. For ex-
ample, viruses displaying relatively low vector angles and
relatively high vector magnitudes are typical of those that
have a more efficient interaction with CCR5 [39,42,51].
The results of single round entry assays in 293-
Affinofile cells showed that in the absence of MVC, the
sensitive and resistant Envs from both subjects had
remarkably similar infectivity profiles; they were highly
sensitive to alterations in CD4 levels but much less sen-
sitive to alterations in CCR5 levels (Figure 4A,B). In fact, at
the lowest CCR5 expression level, these Envs achieved ~50
to ~80% of maximal entry when moderate to high levels ofCD4 were present, suggesting that they all have a relatively
efficient and equivalent ability to interact with unmodified
CCR5. However, in the presence of MVC, the “weakly”
resistant 17-Res Env was highly sensitive to alterations
in both CD4 and CCR5 levels, and even at high levels
of both receptors 17-Res could only achieve ~50% of
the maximal entry achieved when MVC was absent
(Figure 4A). In contrast, in the presence of MVC, the
“strongly” resistant 24-Res Env showed an infectivity pro-
file similar to that which was achieved in the absence of
MVC (Figure 4B). In these cell populations, MVC was
able to inhibit the entry of 17-Sens and 24-Sens Envs, and
inhibited the entry of other MVC-sensitive R5 Envs that
have highly efficient CCR5 usage such as ADA, YU2,
NB6-C3 and NB8-C2 Envs [61,62] (data not shown). To-
gether, these results show that 17-Res Env interacts with
MVC-modified CCR5 inefficiently, whereas 24-Res Env
interacts with MVC-modified CCR5 relatively efficiently.
These results are reflected quantitatively by the VERSA
vector metrics. In the absence of MVC, 17-Sens and
17-Res Envs had similar vector angles of 11.2 ± 1.1°
and 9.0 ± 1.5°, respectively. 24-Sens and 24-Res Envs
also had similar vector angles of 12.9 ± 0.8° and 14.4 ±
1.2°, respectively, in the absence of MVC. These vector
angles are well below the range of what is normally ob-
served for subtype B HIV-1 Envs using this system (30
to 60°) [59,60], indicating highly efficient interactions
with unmodified CCR5. In contrast, the “weakly” resistant
17-Res Env had significantly higher vector angles of 46.4 ±
0.2° for recognition of MVC-bound CCR5 (p < 0.0001 by
an unpaired t test), and significantly lower vector mag-
nitudes which are a measure of overall viral infectivity
(p = 0.048 by an unpaired t test) (Figure 4A, bottom
right panel). The “strongly” resistant 24-Res Env had
much less pronounced increases in vector angles of
22.9 ± 0.5° for recognition of MVC-bound CCR5, yet
these increases were statistically significant (p = 0.0027
by an unpaired t test) (Figure 4B, bottom right panel).
However, 24-Res Env showed no change in vector mag-
nitudes for recognition of MVC-bound CCR5, indicat-
ing no overall reduction in viral infectivity.
Together, the 293-Affinofile infectivity profiles and
VERSA metrics suggest that the development of HIV-1
resistance to MVC in subject 17 compromised the effi-
ciency of interaction between gp120 and CCR5, whereas
the development of resistance in subject 24 did not.
When viewed in the context of the different MPIs to
MVC by these resistant strains, our data illustrate highly
divergent MVC resistance phenotypes by these two
HIV-1 variants that developed in vivo. Our results are in
agreement with those of other studies which suggested
that the magnitude of HIV-1 resistance to CCR5 antago-
nists is dictated by the ability of resistant viruses to
recognize antagonist bound CCR5 [15,36,42,51]. In other
Figure 4 The level of resistance to MVC is dependent on the efficiency of the interaction with MVC-occupied CCR5. 48 differentially
induced 293-Affinofile cell populations were produced as described in Methods, and were infected with luciferase reporter viruses pseudotyped
with Envs from subject 17 (A) or subject 24 (B). Infections of viruses pseudotyped with the MVC-resistant 17-Res and 24-Res Envs were also done
in the presence of 10 µM MVC (lower left panels). For infections in the absence of drug, virus entry levels were normalized to entry achieved in
cells expressing the highest levels of CD4 and CCR5. For infections in the presence of drug, virus entry levels were normalized to entry achieved
in cells expressing the highest levels of CD4 and CCR5 in the absence of drug, as described previously [51]. 17-Sens and 24-Sens Envs were
completely inhibited by MVC in the 293-Affinofile populations (data not shown). The data shown are means of duplicate infections and are
representative of three independent experiments. Shaded wedges along each axis represent increasing concentrations of CD4 and CCR5, as
indicated in the Methods. VERSA metrics were calculated for 17-Res (A, lower right panel) and 24-Res Env (B, lower right panel) in the absence
and presence of drug, as described in Methods. The shaded wedges represent the SEM of the vector angles, and the boxes represent the SEM of
the vector magnitudes.
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the drug-receptor complex compared to free receptor, the
greater the level of resistance. Our results further show, in
two examples of highly divergent resistance levels that
developed in vivo, that there was no change in CD4dependence between the MVC-sensitive and MVC-
resistant Envs, which has been previously reported for a
MVC-resistant Env derived in vitro [63]. Changes in
gp120 binding to CD4 are therefore not likely to be major
pathway to MVC-resistance in subjects failing therapy.
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dependence on the CCR5 N-terminus to escape MVC
inhibition
Previous studies have shown that escape from CCR5 an-
tagonists by resistant viruses that were derived either
in vitro [48,50,51] or in vivo [15,32,38,42] involves HIV-1
adopting an increased reliance on the CCR5 N-terminus,
presumably because this region of CCR5 is not structur-
ally modified by CCR5 antagonists [15]. The extent to
which this occurs in HIV-1 strains that have divergent
MVC resistance levels, however, is unknown.
We therefore next determined the mechanism of en-
gagement between 17-Res and 24-Res Envs and MVC-Figure 5 17-Res and 24-Res Envs exhibit a similar increased depende
pseudotyped with Envs from subject 17 (A) or 24 (B) were used to infect N
mutations in the N-terminus region. Infections were performed in the abse
mutants was normalized to entry obtained in cells expressing an equivalen
virus pseudotyped with a non-functional Env [66] (~1,300 RLU), the entry le
MVC were approximately 60- and 380-fold higher, respectively (~80,000 an
from a compilation of 3 independent experiments. * p<0.05 for increases in
compared to the respective parental sensitive Env. **p<0.05 for increases in
resistant Envs in the absence of drug (unpaired t-test).modified CCR5. Single round entry assays were conducted
in NP2-CD4 cells expressing either wild type (WT) CCR5
or CCR5 containing various mutations in the N-terminal
region using Env-pseudotyped luciferase reporter viruses,
in the presence or absence of MVC (Figure 5). The levels
of virus entry in cells expressing CCR5 mutants were
expressed as percentages of that attained in cells express-
ing equivalent levels of WT CCR5, which was verified by
flow cytometry as described previously [62,64,65] (data
not shown). In the absence of MVC, both 17-Res and 24-
Res Envs displayed significantly increased dependence on
Tyr10, Tyr14 and Tyr15 residues in the CCR5 N-terminus,
which are known to be sulfated in vivo, compared to theirnce on the CCR5 N-terminus. Luciferase reporter viruses
P2-CD4 cells expressing equivalent levels of WT CCR5 or CCR5 with
nce or presence of 10 µM MVC. Viral entry in cells expressing CCR5
t amount of WT CCR5. Compared to background levels of entry by
vels of 17-Res and 24-Res in cells expressing WT CCR5 the presence of
d 500,000 RLU, respectively). The data shown are the means and SEM
the dependence on a particular residue for the resistant Envs
the dependence on a particular residue compared to respective
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ence of MVC when the resistant Envs are “forced” to inter-
act with the drug-modified CCR5 to enter cells, both
17-Res and 24-Res Envs showed a critical reliance not only
on Tyr10, Tyr14 and Tyr15, but also on Asp2, Tyr3, Asp11
and Glu18 residues in the CCR5 N-terminus. 17-Res Env
adopted an increased reliance on Lys22 for recognition of
MVC-bound CCR5, whereas 24-Res Env did not. Neither
Env adopted an increased reliance on Val5.
These results demonstrate a shift to an increased reli-
ance on the CCR5 N-terminus by both MVC-resistant
Envs for interaction with MVC-modified CCR5. Strik-
ingly, the pattern of increased reliance on individual
CCR5 N-terminus residues by 17-Res and 24-Res Envs,
in the absence and presence of MVC, was almost super-
imposable despite widely divergent resistance levels and
widely divergent efficiencies for interaction with MVC-
modified CCR5. This common pattern of increased reli-
ance on CCR5 N-terminus residues is also remarkably
similar to that which we have previously reported for a
MVC-resistant Env that was generated in vitro [51], and
very similar to that which has been previously reported
for a MVC-resistant virus that developed in vivo [15].
Our results illustrate a common molecular pathway to
altered usage of the CCR5 N-terminus as a means for
the two resistant viruses studied to escape MVC, despite
divergent resistance phenotypes and a lack of common
gp120 resistance mutations.Increased reliance on the CCR5 N-terminus renders MVC-
resistant Envs sensitive to neutralization by synthetic,
sulfated peptide fragment of the CCR5 N-terminus
Increased reliance on the CCR5 N-terminus for inter-
action with MVC-bound CCR5 by the resistant Envs,
particularly the increased reliance on the potentially sul-
fated Tyr10, Tyr14 and Tyr15 residues, suggests that this
altered mode of HIV-1 entry into cells may be more sus-
ceptible to being neutralized by sulfated peptide frag-
ments of the CCR5 N-terminus. We therefore produced
a sulfated peptide corresponding to amino acids 1 to 22
of the human CCR5 N-terminus (sCCR51-22). Although
previous studies have employed mammalian expression
systems to incorporate sulfate groups to peptides via the
activity of cellular tyrosylprotein sulfotransferases [67-69],
with this methodology sulfation cannot be regulated nor
can it be incorporated in a homogenous manner, as dem-
onstrated by the failure to achieve sulfation at Tyr15 [69].
To alleviate these limitations, we utilized a site-selective
solid-phase synthetic approach that permits the high
yielding production of sulfated peptides with high purity
(>98%), and which are homogenously sulfated at defined
tyrosine residues [70-72]. This relatively new methodology
was used to produce a synthetic peptide fragment of theCCR5 N-terminus, sCCR51-22, that was sulfated at Tyr10,
Tyr14 and Tyr15.
We first confirmed that the synthetic sCCR51-22 peptide
could completely displace the binding of CD4-bound
gp120 to the 17b gp120 mAb in a dose dependent manner
using an ELISA (data not shown), demonstrating that
sCCR51-22 can bind to CD4-induced gp120 epitopes. We
next tested the ability of sCCR51-22 to inhibit the entry of
the MVC-sensitive and MVC-resistant Envs in the pres-
ence or absence of MVC (Figure 6). As controls we used
an unsulfated version of sCCR51-22, and an unsulfated
peptide that was composed of the same amino acids as
sCCR51-22 but in a scrambled order. The unsulfated and
scrambled peptides had no affect on the infectivity of any
of the Envs tested, regardless of whether MVC was
present or absent. The sCCR51-22 peptide was not capable
of inhibiting the infectivity of any of the Envs in the
absence of MVC, and indeed, they showed some enhance-
ment of infectivity when the MVC-resistant and MVC-
sensitive Envs were permitted to interact with unmodified
CCR5. This enhancement of infectivity may represent some
“pre-triggering” of gp120 to facilitate entry into cells via a
favored interaction with the CCR5 ECLs. However,
sCCR51-22 could inhibit the entry of 17-Res (Figure 6A)
and 24-Res Envs (Figure 6B) in the presence of MVC, when
these Envs were forced to interact with MVC-modified
CCR5 via an increased reliance on the CCR5 N-terminus.
Interestingly, the “weakly” resistant 17-Res Env could
be completely inhibited by 100 μM sCCR51-22 in NP2-
CD4/CCR5 cells, whereas the “strongly” resistant 24-Res
Env was only partially inhibited. Because 24-Res Env has
a more efficient interaction with MVC-bound CCR5
than 17-Res Env (see Figure 4), we hypothesized that 24-
Res Env has increased affinity for the CCR5 N-terminus
in the presence of MVC than 17-Res Env, which was
outcompeting sCCR51-22. To test this hypothesis we re-
peated the experiment in JC53 cells, which express sub-
stantially lower levels of CCR5 than NP2-CD4/CCR5
cells [58]. We reasoned that reducing the amount of
available native CCR5 N-terminus would lead to greater
inhibition of 24-Res Env in the presence of MVC by
sCCR51-22, and in this cell line we showed that 24-Res
could be completely inhibited by 100 µM sCCR51-22
(Figure 7). These results suggest that the inhibitory
mechanism of sCCR51-22 is competitive, and that 17-Res
and 24-Res Envs have different affinities for the CCR5 N-
terminus when interacting with MVC-bound CCR5. How-
ever, further inhibition studies in JC53 cells with 24-Sens
Env in the absence of MVC are required to confirm this
assertion. Our results also confirm that sulfation of the
CCR5 N-terminus is critical for interaction with gp120 [5].
These results are consistent with the those of previous
studies which showed that an antibody directed to the
CCR5 N-terminus (CTC5) was able to neutralize the
Figure 6 A sulfated mimic of the CCR5 N-terminus can inhibit entry of MVC-resistant Envs. NP2-CD4/CCR5 cells were preincubated with
increasing concentrations of scrambled, unsulfated or sulfated sCCR51-22 peptide prior to infection with luciferase reporter viruses pseudotyped
with Envs from subject 17 (A) or 24 (B). Infections of viruses pseudotyped with 17-Res and 24-Res Envs were also performed in the presence of
10 µM MVC. The data are expressed as the percentage entry of that obtained in cells incubated with no inhibitor. Data points shown are the
mean and SEM of triplicates, and are representative of three independent experiments.
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not sensitive viruses [32,49,50], confirming the importance
of interactions with the CCR5 N-terminus as a route for
HIV-1 escape from CCR5 antagonists. Moreover, these re-
sults suggest a new avenue for development of HIV-1
therapeutics that could be useful for treating patients with
resistance to CCR5 antagonists, or which could prevent
resistance from occurring if co-administered with CCR5
antagonists. Whilst 100 µM concentrations are certainly
not favorable for any peptide inhibitor, proof of principal
is demonstrated here, and potency may potentially be in-
creased by further development of sulfopeptidomimetic
compounds based on the CCR5 N-terminus.Both 17-Res and 24-Res Envs adopt an altered
mechanism of interaction with the CCR5 ECLs to escape
MVC inhibition
HIV-1 strains that evolved resistance to MVC in vitro or
in vivo and display a narrow cross resistance profile have
been shown to remain dependent on the MVC-modified
CCR5 ECLs for entry [15,51]. To determine whether this
is the case for HIV-1 strains that have divergent MVC
resistance levels, we next conducted single round entry
assays in NP2-CD4/CCR5 cells expressing equivalent
levels of either WT CCR5 or CCR5 containing various
mutations in the ECL1, ECL2 or ECL3 region using Env-
pseudotyped luciferase reporter viruses, in the presence
Figure 7 Inhibition of 24-Res Env by sCCR51-22 is more
pronounced in cells expressing lower levels of CCR5. JC53 cells,
which express substantially lower levels of CCR5 than NP2-CD4/CCR5
cells [58], were infected with luciferase reporter viruses pseudotyped
with 24-Res Env in the presence of 10 µM MVC and increasing
concentrations of either scrambled peptide or sulfated sCCR51-22
peptide. The data are expressed as the percentage entry of that
obtained in cells incubated with no inhibitor. The data points shown
are the mean and SEM of triplicates, and are representative of three
independent experiments.
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and expressed as described above. In the absence of
MVC, both 17-Res and 24-Res displayed similar profiles
of dependence on these regions as compared to their
parental sensitive Envs, at least with the CCR5 mutants
tested (Figure 8). However, in the presence of MVC, 17-
Res and 24-Res Envs both became critically reliant on
His88 and His181 in the CCR5 ECL1 and ECL2 regions,
respectively, which is similar to the pattern of increased
reliance on these residues that we have reported for a
MVC-resistant strain that was generated in vitro [51].
17-Res Env also adopted an increased reliance on
Tyr184 and Phe264 in the CCR5 ECL2 and ECL3 re-
gions, respectively, whereas 24-Res Env did not. Thus, in
addition to adopting a common mechanism of increased
reliance on the CCR5 N-terminus (see Figure 5), MVC-
resistant Envs also appear to adopt a common pattern of
increased reliance on histidine residues in the CCR5
ECL1 and ECL2 regions, despite divergence in resistance
levels and differing efficiencies for recognition of the
drug-modified ECLs (see Figure 4).
To confirm that 17-Res and 24-Res Envs maintained a
critical interaction with the MVC-modified CCR5 ECLs
for HIV-1 entry into cells, we next performed virus in-
hibition assays in NP2-CD4/CCR5 cells using the 2D7
mAb, which is directed against the ECL2 region of
CCR5 (Figure 9). All the Envs remained sensitive to
inhibition by 2D7 when HIV-1 entry proceeded either
via unmodified CCR5 or MVC-bound CCR5, confirmingthat both 17-Res and 24-Res still require contact with
the MVC-modified CCR5 ECLs to escape MVC. These
results are consistent with those of another study of a
MVC-resistant strain that was generated in vivo, which
also showed a requirement of MVC-resistant HIV-1 to
interact with the drug modified ECLs [15]. Interestingly,
this study also demonstrated an increased reliance of
MVC-resistant virus on His88 and His181, although not
to the same degree that we saw for 17-Res and 24-Res
Envs. The requirement of all the presently characterized
MVC-resistant HIV-1 Envs to maintain interactions with
the drug-modified ECLs, regardless of whether they were
generated in vivo or in vitro [15,51], may help explain why
these Envs lack appreciable cross resistance to other
CCR5 antagonists or display only narrow cross resistance.
Potential structural alterations between gp120 and
the CCR5 N-terminus distinguish MVC-resistant from
MVC-sensitive Envs
To identify potential structural alterations associated
with MVC resistance, we constructed full-length three-
dimensional (3D) homology models of gp120s of 17-Sens,
17-Res, 24-Sens and 24-Res Envs based on the crystal
structure of CD4-bound YU2 gp120 [73]. This structure is
particularly useful because it has an intact V3 loop and is
docked to a CCR5 N-terminal region peptide (CCR52-17),
and thus permits the investigation of the molecular inter-
actions between the CCR5 N-terminus and the stem of the
V3 loop and the gp120 bridging sheet. However, a limita-
tion of homology modeling of this system is that generally
only a single conformation of the V3 loop and the CCR5
residues can be considered. Therefore, we have taken a
conservative approach that relies on the data inherent in
the available crystal (gp120) and NMR (CCR5 N-terminal
region) structures used as templates to derive the hom-
ology models. With these limitations in mind, we provide
below structural interpretations of the homology models in
the context of our current experimental findings.
The homology models with potential alterations in inter-
action networks between the CCR5 N-terminus and gp120
of MVC-sensitive and MVC-resistant Envs from subjects
17 and 24 are shown in Figures 10 and 11, respectively,
and a summary of the potential bonding networks is
shown in Table 2. Compared to 17-Sens gp120, the 17-Res
gp120 model showed a loss of a possible hydrogen bond
formed between Ile323 of gp120 and sulfated Tyr10 of
CCR5, but a potential gain of two ionic (ie, electrostatic)
interactions formed between Arg440 of gp120 and Asp11
of CCR5, which was associated with repositioning of
Arg440 from the gp120 bridging sheet. Four hydrogen
bonds between gp120 and the CCR5 N-terminus were
common for both 17-Sens and 17-Res Envs, which in-
cluded 2 bonds formed between Asn302 of gp120 and sul-
fated Tyr14 of CCR5, Thr303 of gp120 and sulfated Tyr14
Figure 8 17-Res and 24-Res Envs exhibit a similar altered recognition of the CCR5 ECLs. Luciferase reporter viruses pseudotyped with Envs
from subject 17 (A) or 24 (B) were used to infect NP2-CD4 cells expressing equivalent amounts of WT CCR5 or CCR5 with mutations in the ECL1,
ECL2 and ECL3 regions. Infections were performed in the absence or presence of 10 µM MVC. Viral entry in cells expressing CCR5 mutants was
normalized to entry obtained in cells expressing an equivalent amount of WT CCR5. In these experiments, MVC completely inhibited the entry of
17-Sens and 24-Sens Envs, regardless of the Env mutant tested (data not shown). The data shown are the means and SEM from a compilation of
3 independent experiments. **p<0.05 for increases in the dependence on a particular residue compared to respective resistant Envs in the
absence of drug (unpaired t-test).
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CCR5. In contrast, the 24-Res gp120 model displayed a
more extensive network of potential bonds formed be-
tween gp120 and the CCR5 N-terminus compared to 24-
Sens, with the only predicted interaction shared by both
24-Sens and 24-Res Envs being a hydrogen bond formed
between Thr303 of gp120 and sulfated Tyr14 of CCR5. Im-
portantly, compared to 24-Sens which possibly had one salt
bridge between Lys207 of gp120 and sulfated Tyr14 of
CCR5, the 24-Res model contained a more complex net-
work of 7 electrostatic interactions between gp120 and
CCR5, all formed with sulfated Tyr14 of CCR5.
These results suggest that the two MVC resistant Envs
have structural differences involved in their altered en-
gagement with the CCR5 N-terminus. Whilst sulfated
Tyr14 seems to be a common “anchor” point for Envs
from both subjects, regardless of whether they are resist-
ant or sensitive to MVC, 24-Res Env potentially forms amore extensive network of interactions with sulfated
Tyr14 compared to 24-Sens Env. 17-Res Env, on the
other hand, may participate in one less interaction with
sulfated Tyr14 compared to 17-Sens Env, but may have
two additional electrostatic interactions with Asp11 of
CCR5. These structural models help reconcile the differ-
ences in MVC resistance phenotypes and abilities to
interact with MVC-bound CCR5 between 17-Res and
24-Res Envs. The more extensive bonding network
formed by the “strongly” resistant 24-Res Env may result
in greater affinity for the CCR5 N-terminus, and thus
may underlie the highly efficient interaction with MVC-
bound CCR5 that is demonstrated by the affinity profiling
studies (see Figure 4). This may also explain why 24-Res
Env was considerably less sensitive to inhibition by the
sCCR51-22 peptide than 17-Res Env (see Figure 6).
Interestingly, our molecular modeling studies suggest that
none of the V3 loop changes that were shown to be the
Figure 9 MVC-resistant Envs remain sensitive to inhibition by
the CCR5 ECL2-directed antibody 2D7. NP2-CD4/CCR5 cells were
preincubated with increasing concentrations of 2D7 prior to
infection with luciferase reporter viruses pseudotyped with Envs
from subject 17 (A) or 24 (B). Infections with 17-Res and 24-Res Envs
were also performed in the presence of 10 µM MVC. The data are
expressed as percentage inhibition, where inhibition in untreated
cells was set to zero. The data shown are the mean and SEM of
three independent experiments. Inhibition curves were constructed
using Prism, version 4.0c (GraphPad).
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and 3) were directly involved in the altered bonding net-
works formed by the resistant Envs. Instead, these amino
acids may alter the conformation and integrity of the V3
loop [51], indirectly facilitating different bonding patterns
between the CCR5 N-terminus and other gp120 residues.
This interpretation, which is consistent with the current
view of how HIV-1 can adopt altered use of CCR5 to
escape CCR5 antagonists [74], provides a possible explan-
ation as to why V3 loop mutations conferring resistance
to MVC and other CCR5 antagonist are almost always
strain specific.Conclusions
Together, the results of our study show that resistance to
MVC, the only CCR5 antagonist approved for use as an
antiretroviral therapy for treatment of HIV-1 infection,can develop to different extents in HIV-1 infected sub-
jects. HIV-1 can develop comparatively “weak” or “strong”
resistance in vivo, as a result of acquiring a relatively inef-
ficient or efficient ability to recognize the MVC-bound
conformation of CCR5, respectively, and involves strain-
dependent resistance mutations that indirectly facilitate an
altered interaction with the CCR5 N-terminus. Because
there is no available crystal structure of gp120 bound to
the CCR5 ECLs, it remains unclear as to whether the
V3 loop resistance mutations are directly or indirectly
involved in maintaining interactions between the MVC-
resistant Envs and the drug-modified ECLs. Despite
highly divergent resistance phenotypes and abilities to
recognize MVC-modified CCR5, and lack of common
resistance mutations, the molecular pathway to resist-
ance by the Envs studied is remarkably similar; this path-
way involves HIV-1 adopting a critical reliance on the
CCR5 N-terminus, in particular on the sulfated tyrosine
residues, and an altered interaction with the CCR5 ECL1
and ECL2 regions, in particular with histidine residues.
Together, our study provides new mechanistic insights
into the development of resistance to MVC in vivo. Fur-
thermore, the increased reliance on sulfated CCR5 N-
terminus residues suggests a new avenue to block HIV-1
entry by CCR5 N-terminus sulfopeptidomimetic drugs.
Methods
Cells
293T cells, JC53 cells [75], NP2-CD4 and NP2-CD4/CCR5
cells [76] were maintained in Dulbecco’s Modified Eagles
Medium (DMEM) supplemented with 10% (vol/vol) fetal
calf serum (FCS) and 100 µg per ml of penicillin and
streptomycin. CD4 selection in NP2 cells was maintained
by 500 µg per ml of G418 and CCR5 expression was
maintained by 1ug per ml of puromycin. 293-Affinofile
cells [59] were maintained in DMEM supplemented with
10% (vol/vol) FCS, 100 µg per ml of penicillin and strepto-
mycin, 50 µg per ml of blasticidin and 200 µg per ml of
G418. Peripheral blood mononuclear cells (PBMC)
were purified from the blood of healthy HIV-1 negative
donors, stimulated with 5 µg of phytohemagglutinin
(Sigma) per ml for 2 days and cultured in RPMI 1640
medium supplemented with 10% (vol/vol) FCS, 100 µg
per ml of penicillin and streptomycin, and 20 U per ml
of interleukin-2 (Roche).
Env cloning
Infectious recombinant viruses containing the env gene from
subjects who had failed MVC therapy with demonstrable
MVC resistance and from the baseline samples of the same
subjects [52,56] were used for Env subcloning. To character-
ise the env genes from these recombinant viruses in a re-
porter based system, the 2.1-kb Kpn1-BamH1 env fragment,
corresponding to nucleotide positions 6348–8478 in HXB2,
Figure 10 Potential molecular interactions between gp120 of 17-Sens and 17-Res Envs and the CCR5 N-terminus. Homology models of
sensitive and resistant gp120 protein sequences were created using a crystal structure of YU2 gp120 bound to CD4 and a sulfated CCR5 N-
terminus peptide mimic [73]. Models of 17-Sens (A) and 17-Res (B) are represented as grey ribbons. Amino acids involved in bonding between
gp120 and the CCR5 N-terminus are shown as sticks. The Arg440 side chain is shown in green, to illustrate its potential repositioning from the
bridging sheet in 17-Res Env. Purple; CCR52-17 N-terminus peptide, green dashed lines; bonds.
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cloned into the pSVIII-Env expression plasmid [77], as de-
scribed previously [61,78]. 17-Sens, 17-Res, 24-Sens and
24-Res Envs were shown to be functional and able to sup-
port HIV-1 entry into JC53 cells when pseudotyped onto
Env-deficient luciferase reporter viruses (data not shown).
Envs were sequenced, and have been assigned GenBank
accession numbers KC834602 to KC834605.Env mutagenesis
All gp120 mutants were synthesized by GenScript Pty.
Ltd. (Piscataway, NJ, USA), and subcloned into thepSVIII-Env expression vector [79]. The authenticity of the
gp120 mutants was verified by full-length sequencing.Production and titration of Env-pseudotyped luciferase
reporter viruses
Env-pseudotyped luciferase reporter viruses were pro-
duced by transfection of 293T cells with plasmids
pCMVΔP1ΔenvpA, pHIV-1Luc, and pSVIII-Env using
lipofectamine 2000 (Invitrogen) at a ratio of 1:3:1, as de-
scribed previously [61,78,80]. Supernatants were harvested
48 h later, filtered through 0.45 µM-pore size filters, and
stored at −80°C. The 50% tissue culture infective doses
Figure 11 Potential molecular interactions between gp120 of 24-Sens and 24-Res Envs and the CCR5 N-terminus. Homology models of
sensitive and resistant gp120 protein sequences were created using a crystal structure of YU2 gp120 bound to CD4 and a sulfated CCR5 N-
terminus peptide mimic [73]. Models of 17-Sens (A) and 17-Res (B) are represented as grey ribbons. Amino acids involved in bonding between
gp120 and the CCR5 N-terminus are shown as sticks. Purple; CCR52-17 N-terminus peptide, green dashed lines; bonds.
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JC53 cells [75], as described previously [61,78].
Synthesis of sulfated peptide mimics of the CCR5
N-terminus
The triply sulfated sCCR51-22 peptide (MDYQVSSPIYDI
NYYTSEPSQK; sulfated at Tyr10, Tyr14 and Tyr15) was
synthesized using Fmoc-strategy solid-phase synthesis onRink amide resin using commercially available Fmoc-
protected amino acids and a synthetic neopentyl-protected
sulfotyrosine residue, as we and our collaborators have de-
scribed previously for CCR3 [71,72]. In this synthesis, Cys20
was modified to serine to prevent the formation of inter-
strand disulfide bonds. The crude sulfopeptide was cleaved
from the resin using a solution of trifluoroacetic acid/
triisopropylsilane/thioanisole/water (85:0.5:0.5:0.5 v/v/v/v)
Table 2 Potential bond networks formed by HIV-1 Envs







17-Sens Asn302: Hδ21 sTyr14:OH H




17-Res Asn302:Hδ21 sTyr14:OH H
Asn302:Hδ21 sTyr14:O3 H
Thr303:HN sTyr14:O2 H
Arg440:Hη12 Asp11: Oδ1 I
Arg440:Hη22 Asp11: Oδ1 I
Gly441:HN sTyr14: Oδ1 H

















The gp120 residues involved in interactions with the CCR5 N-terminus are
numbered according to the HXB2 gp120 sequence. Bonding networks were
determined as described in Methods. H, Hydrogen bond; I, Ionic hydrogen
bond; Hη21, delta hydrogen atom 1; HN, backbone nitrogen; Hη11, eta
hydrogen atom 1,1; Hη12, eta hydrogen atom 1,2; Hη21, eta hydrogen atom
2,1; Hη22, eta hydrogen atom 2,2; Hη1, zeta hydrogen atom 1; OH, hydroxyl;
O, oxygen; O1, oxygen atom 1; O2; oxygen atom 2; O3, oxygen atom 3; Oδ1,
delta oxygen atom 1.
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lution in vacuo, the crude sulfopeptide was suspended in
MilliQ water (1 mg/mL) and sodium azide (50 equiv) was
added in a single portion. The mixture was warmed to 70°C
and stirred for 16 hours. The mixture was concentrated by
lyophilization before purification by preparative reversed-
phase HPLC (linear gradient of 0% 0.1 M ammonium
acetate to 45% acetontrile in 0.1 M ammonium acetate
over 60 min; Rt = 30 min). The sulfopeptide was lyophi-
lized three times from MilliQ water until a constantweight was achieved. The sulfopeptide was produced as a
white solid (55 mg, 7.5%, based on the original resin
loading).
HIV-1 inhibition assays
NP2-CD4/CCR5 cells (1×104 in 100 µl) were seeded in
flat-bottom 96-well plates 24 h prior to infection. PBMC
(2×105 in 100 µl) were seeded in U-bottom 96-well plates
at the time of infection. The CCR5 antagonists MVC, VCV
and TAK-779 were resuspended in dimethyl sulfoxide
(DMSO). CCR5 N-terminus peptides were resuspended in
DMSO. The anti-CCR5 antibody 2D7 was resuspended in
phosphate buffered saline (PBS). Prior to infection the
media was removed from cells and replaced with 100 µl of
fresh media with five-fold dilutions of inhibitor (at a ×2
concentration) for 30 min at 37°C. The concentration
range for MVC, VVC and TAK-779 was 5 µM to 0.064 nM;
for CCR5 N-terminus peptides the concentration range was
100 µM to 1.28 nM; for 2D7 the concentration range was
25 µg/ml to 0.32 ng/ml. The concentration of DMSO
(0.1%, vol/vol) or PBS (2.5%, vol/vol) was maintained in the
untreated wells. NP2-CD4/CCR5 cells were infected with
200 TCID50 of Env-pseudotyped luciferase reporter viruses
in 100 µl for 12 h at 37°C. PBMC were infected with 2000
TCID50 of Env-pseudotyped luciferase reporter viruses in
100 µl for 12 h at 37°C. Following this, the inoculum was
removed and replaced with fresh media. The inhibitor con-
centrations were maintained throughout the subsequent
culture period. NP2-CD4/CCR5 were incubated at 37°C for
a total of 72 h, and PBMC were incubated at 37°C for a
total of 96 h.
The level of HIV-1 entry was measured by luciferase
activity in cell lysates (Promega) according to the manu-
facturers protocol. Luminescence was measured using a
FLUOStar microplate reader (BMG). Background activity
was assessed by mock-infected cells and was subtracted
from all wells. The amount of luciferase in cells treated
with an inhibitor was expressed as a percentage of that in
untreated cells. The percentage of inhibition was calcu-
lated by subtracting this number from 100. The data were
fitted with a nonlinear function, and alterations in inhibi-
tor sensitivity were assessed by reductions in the MPI as
described previously [34].
293-Affinofile assays and quantitative vector analysis
293-Affinofile cells were infected with Env-pseudotyped
luciferase reporter viruses as described previously
[51,59,65] (reviewed in [60]). Briefly, 48 populations of
cells expressing different combinations of CD4 and
CCR5 levels were generated by inducing cells with 2-fold
serial dilutions of minocycline (0.156 to 5.0 ng/ml) and
ponasterone A (0.0156 to 2.0 µM). CD4 and CCR5 con-
centrations were determined by quantitative flow cytome-
try (qFACS) as described previously [59,81]. The induced
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with 10 µM MVC for 30 min at 37°C, after which they
were inoculated with 200 TCID50 of Env-pseudotyped lu-
ciferase reporter viruses and were analyzed for levels of
HIV-1 entry as described above. In experiments using
MVC-treated cells, the MVC concentration was main-
tained throughout the culture period. The relative level of
virus entry achieved by each Env test was expressed as a
percentage of that achieved in 293-Affinofile cells express-
ing the highest concentrations of CD4 and CCR5. For in-
fections done in the presence of MVC, virus entry was
expressed as a percentage of that achieved in untreated
wells.
The relative dependence of Env-pseudotyped reporter
viruses on CD4 and CCR5 expression levels was math-
ematically modeled using the VERSA computational
platform (http://versa.biomath.ucla.edu), as described
previously [51,59,65] (reviewed in [60]). With this model,
viral infectivity is quantified using a single vector. The
vector magnitude reflects the efficiency of viral entry,
and the vector angle represents the relative dependence
on CD4 and CCR5. In theoretical extremes, viruses that
have the greatest possible sensitivity to alterations in
CD4 expression but are not affected by alterations in
CCR5 expression have a vector angle of 0°, and con-
versely, viruses that have the greatest possible sensitivity
to alterations in CCR5 expression but are not affected by
alterations in CD4 expression have a vector angle of 90°.
Entry assays in cells expressing CCR5 mutants
NP2-CD4 cells transfected with WT or mutant CCR5
were infected with Env-pseudotyped luciferase reporter
viruses as described previously [51,65]. Briefly, NP2-CD4
cells were transfected with plasmids expressing WT
CCR5 or CCR5 with alternative mutations in the N-
terminus, ECL1, ECL2 or ECL3 regions. The WT CCR5
plasmid was serially diluted (2-fold) to create popula-
tions of cells expressing a range of CCR5. These cells
were used to create a standard curve of expression of
which the expression of mutant CCR5 expressing cells
could be matched to. Expression of CCR5 was deter-
mined by flow cytometry using the CCR5-specific anti-
bodies 2D7 (BD Pharmingen) or CTC5 (R&D Systems).
Cells were either left untreated or treated with 10 µM of
MVC for 30 min at 37°C, after which they were inocu-
lated with 200 TCID50 of Env-pseudotyped luciferase
reporter viruses. Cells were cultured for a total of 72 h
and in experiments using MVC-treated cells, the MVC
concentration was maintained throughout the culture
period. Cells were analyzed for levels of HIV-1 entry as
described above, and the entry of Env-pseudotyped lucif-
erase reporter viruses in cells expressing mutant CCR5
was expressed as a percentage of that achieved in cells
expressing an equivalent level of WT CCR5.gp120 structural modeling
Three-dimensional protein structures of 17-Sens, 17-Res,
24-Sens and 24-Res gp120 sequences were prepared using
the Discovery Studio suite, version 3.0 (Accelrys, San
Diego, CA), as described previously [62,82]. The crystal
structure of CD4-bound YU-2 gp120 containing the V3
variable loop docked with the nuclear magnetic resonance
(NMR) structure of a sulfated N-terminal peptide of
CCR5 (residues 2 to 15) (kindly provided by P. D. Kwong
[73]) was used as a template. Harmonic restraints were
applied prior to optimization using the Steepest Descent
protocol, which incorporates iterative cycles of conjugate-
gradient energy minimization against a probability density
function that includes spatial restraints derived from the
template and residue specific properties [83]. Hydrogen
bonds between gp120 and the CCR5 peptide were mod-
eled with the Monitor H-bonds protocol in Discovery
Suite 3.0, using the distance criterion of 2.5 Å and
selecting for intermolecular bonds only.
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